Download PDF
Nuklearmedizin 1985; 24(03): 111-114
DOI: 10.1055/s-0038-1624288
Short Communications – Kurzmitteilungen
Schattauer GmbH

Scintigraphic Detection of Experimental Myocardial Infarction with 99mTc-Heparin in the Dog

Szintigraphischer Nachweis des experimentellen Myokardinfarktes mit 99mTc-Heparin beim Hund
F. Duška
1   From the Departments of Normal and Pathological Physiology, of Nuclear Medicine and of Morphological Sciences, Charles University, Faculty of Medicine, Hradec Krâlové, Czechoslovakia
,
P. Kafka
1   From the Departments of Normal and Pathological Physiology, of Nuclear Medicine and of Morphological Sciences, Charles University, Faculty of Medicine, Hradec Krâlové, Czechoslovakia
,
J. Kubíček
1   From the Departments of Normal and Pathological Physiology, of Nuclear Medicine and of Morphological Sciences, Charles University, Faculty of Medicine, Hradec Krâlové, Czechoslovakia
,
J. Vižda
1   From the Departments of Normal and Pathological Physiology, of Nuclear Medicine and of Morphological Sciences, Charles University, Faculty of Medicine, Hradec Krâlové, Czechoslovakia
,
Y. Mazurová
1   From the Departments of Normal and Pathological Physiology, of Nuclear Medicine and of Morphological Sciences, Charles University, Faculty of Medicine, Hradec Krâlové, Czechoslovakia
› Author Affiliations
Further Information

Publication History

Received: 19 February 1985

in revised form: 07 June 1985

Publication Date:
20 January 2018 (online)

    Permissions and Reprints

Summary

Experimental infarctions were produced in 12 dogs by ligation of the Ramus interventricularis anterior of the left coronary artery, and their uptake of 99mTc-heparin was measured 7, 24 and 48 h as well as 7 days thereafter by recording an in vivo chest scintigram 4 h after intravenous injection of the compound. The dogs were subsequently killed, the heart removed and an in vitro scintigram obtained. Finally, the uptake of the compound was measured in tissue samples. The results indicate that 99mTc-heparin is accumulated in lesions which are not older than 24 h. At the other points in time uptake is low but even 24-h old lesions cannot be demonstrated reliably. The results are impaired by the high blood activity on the cardiac chambers and by the background activity of the lungs. In general, 99mTc-heparin has less useful properties than the more frequently employed 99mTc-pyrophosphate so that a change of procedure is not to be recommended.

Zusammenfassung

Bei 12 Hunden wurden durch Unterbindung des Ramus interventricularis anterior der linken Koronararterie experimentelle Infarkte hervorgerufen. Die Anreicherung von 99mTc-Heparin wurde in 7, 24 und 48 h sowie in 7 Tage alten Infarkten gemessen. Eine Szintigraphie des Brustkorbes in vivo wurde 4 h nach i. v. Applikation des Radiopharmakons durchgeführt. Danach wurden die Hunde getötet, das Herz herausgenommen und eine Szintigraphie in vitro vorgenommen. Zum Schluß wurde die Anreicherung des Radiopharmakons in Gewebsproben überprüft. Die Ergebnisse bewiesen, daß sich 99mTc-Heparin nur in bis zu 24 h alten Läsionen anreichert. In den übrigen Zeitintervallen ist die Anreicherung gering. Aber auch 24 h alte Nekrosen können nicht zuverläßlich dargestellt werden. Die Ergebnisse werden verschlechtert durch die hohe Blutaktivität in den Herzhöhlen und die hohe Hintergrundaktivität in der Lunge. Allgemein weist 99mTc-Heparin schlechtere Eigenschaften auf als das häufiger benutzte 99mTc-Pyrophosphat auf, so daß seine Anwendung nicht empfohlen werden kann.

 

  • References

  • 1 Duška F, Bradna P, Novák J, Kubíček J, Vižda J, Kafka P, Mazurová Y, Bláha V. Pyrophosphate heart scan in patients with progressive systemic sclerosis. Brit. Heart J. 1982; 47: 90-3.
    CrossrefPubMedGoogle Scholar
  • 2 Duška F, Vižda J, Kubíček J, Kafka P, Nesvadba Z, Ždánský P, Baštecký J. The sensitivity of scintigraphic myocardial imaging by the use of 99mTc-labelled pyrophosphate in the diagnosis of cardiomyopathy of various etiology. Eur. J. nucl. Med. 1979; 87-90.
    PubMedGoogle Scholar
  • 3 Esquerre J. P, Guirand R. Modified 99mTc-heparin for the imaging of acute experimental myocardial infarcts. J. nucl. Med. 1980; 21: 1202.
    PubMedGoogle Scholar
  • 4 Kulkarini P. V, Parkey R. W, Buja L. M, Wilson J. E, Bonte F. J, Willerson J. T. Technetium-labelled heparin: Preliminary report of a new radiopharmaceutical with potential for imaging damaged coronary arteries and myocardium. J. nucl. Med. 1978; 19: 810-5.
    PubMedGoogle Scholar
  • 5 Kulkarini P. V, Parkey R. W, Wilson J. E, Lewis S. E, Buja L. M, Bonte F. J, Willerson J. T. Modified 99mTc-heparin for the imaging of acute experimental myocardial infarcts. J. nucl. Med. 1980; 21: 117-21.
    PubMedGoogle Scholar
  • 6 Kuntsen K. M, Otterstad J. E, Strom O. Myocardial scintigraphy with 99mtechnetium stannous pyrophosphate infarction. Acta med. Scand. 1977; 202: 107-11.
    Google Scholar
  • 7 Parkey R. W, Bonte F. J, Stokely E. M, Meyer S. C, Willerson J. T. Analysis of WmTc-stannous pyrophosphate (PYP) myocardial scintigrams in 242 patients. J. nucl. Med. 1975; 16: 556.
    Google Scholar
  • 8 Perez L. A, Mayt D. B, Freeman L. M. Localization of myocardial disorders other than infarction with WmTc- labeled phosphate agents. J. nucl. Med. 1976; 17: 241-6.
    PubMedGoogle Scholar
  • 9 Polivar L, Parkey R. W, Bonte F. J, Stokely E. M, Buja L. M, Willerson J. T. Technetium-99m stannous pyrophosphate myocardial scintigrams to recognize acute subendocardial myocardial infarcts in patients. Amer. J. Cardiol. 1976; 37: 162.
    Google Scholar
  • 10 Strauss H. W, Harrison K, Laugan J. K, Lehowitz E, Pitt B. Thallium-201 for myocardial imaging. Circulation 1975; 51: 641-5.
    CrossrefPubMedGoogle Scholar
  • 11 Waders T. J. Th, Schoot J. B, Sohole E. B, Saneson G, Niftrich G. J, Lie K. I, Dureas D, Wellens H. J. Noninvasive visualization of acute myocardial infarction with thallium 201. Brit. Heart J. 1975; 37: 741-4.
    CrossrefPubMedGoogle Scholar